L.E.A.F. Pharmaceuticals Receives Positive US FDA Feedback and Comprehensive Roadmap for Clinical Development as well as Registration of its Four Lead Novel Anticancer Drugs

US FDA further indicates that one of the four drugs may be eligible for registration via 505(b)(2) Regulatory Pathway VALLEY FORGE, Pennsylvania, Oct. 29, 2018 /PRNewswire/ -- L.E.A.F. Pharmaceuticals LLC ("LEAF"), a global pharmaceutical company focused on developing novel anticancer...

from PR Newswire: //https://ift.tt/2PqKtey